Evidence map›Paper›PMID 38317193›Full record

ArticleCancer cell international2024

Targeting of H19/cell adhesion molecules circuitry by GSK-J4 epidrug inhibits metastatic progression in prostate cancer.

Valeria Pecci, Fabiola Troisi, Aurora Aiello, Sara De Martino, Angela Carlino, Vincenzo Fiorentino, Cristian Ripoli, Dante Rotili, Francesco Pierconti, Maurizio Martini and 10 more

Abstract read
In one paragraph

Article in Cancer cell international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Valeria PecciDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, 00168, Italy.
Fabiola TroisiDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, 00168, Italy.
Aurora AielloNational Research Council (CNR)-IASI, Rome, Italy.
Sara De MartinoDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, 00168, Italy.
Angela CarlinoFondazione "Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.
Vincenzo FiorentinoFondazione "Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.
Cristian RipoliFondazione "Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.
Dante RotiliDipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Rome, Italy.
Francesco PiercontiFondazione "Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.
Maurizio MartiniFondazione "Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.
Manuela PorruTranslational Oncology Research Unit, IRCCS- Regina Elena National Cancer Institute, Rome, Italy.
Francesco PintoFondazione "Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.
Antonello MaiDipartimento di Chimica e Tecnologie del Farmaco, Sapienza Università di Roma, Rome, Italy.
Pier Francesco BassiDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, 00168, Italy.
Claudio GrassiFondazione "Policlinico Universitario A. Gemelli IRCCS", Rome, Italy.
Carlo GaetanoLaboratory of Epigenetics, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy.
Alfredo PontecorviDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, 00168, Italy.
Lidia StrigariDepartment of Medical Physics, S. Orsola, Malpighi University Hospital, Bologna, Italy.
Antonella FarsettiNational Research Council (CNR)-IASI, Rome, Italy. antonella.farsetti@cnr.it.
Simona NanniDepartment of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, 00168, Italy. simona.nanni@unicatt.it.

Funding

EU-CardioRNA COST Action CA17129Fondazione AIRC per la ricerca sul cancro ETS AIRC under IG 2019-ID 22858 project-PI Nanni SimonaMinistero della Salute RF-2019-12370266Ministero dell'Istruzione, dell'Università e della Ricerca PRIN2017S55RXBMinistero dell'Università e della Ricerca FISR2019_00374Regione Lazio project ID A0375-2020-36597Regione Lombardia progetto "Immunhub"Ricerca Corrente Progetto di Rete Aging "Promising" Ricerca Corrente 2021
6 · The paper itself

Abstract

backgroundAbout 30% of Prostate cancer (PCa) patients progress to metastatic PCa that remains largely incurable. This evidence underlines the need for the development of innovative therapies. In this direction, the potential research focus might be on long non-coding RNAs (lncRNAs) like H19, which serve critical biological functions and show significant dysregulation in cancer. Previously, we showed a transcriptional down-regulation of H19 under combined pro-tumoral estrogen and hypoxia treatment in PCa cells that, in turn, induced both E-cadherin and β4 integrin expression. H19, indeed, acts as transcriptional repressor of cell adhesion molecules affecting the PCa metastatic properties. Here, we investigated the role of H19/cell adhesion molecules circuitry on in vivo PCa experimental tumor growth and metastatic dissemination models.

methodsH19 was silenced in luciferase-positive PC-3 and 22Rv1 cells and in vitro effect was evaluated by gene expression, proliferation and invasion assays before and after treatment with the histone lysine demethylase inhibitor, GSK-J4. In vivo tumor growth and metastasis dissemination, in the presence or absence of GSK-J4, were analyzed in two models of human tumor in immunodeficient mice by in vivo bioluminescent imaging and immunohistochemistry (IHC) on explanted tissues. Organotypic Slice Cultures (OSCs) from fresh PCa-explant were used as ex vivo model to test GSK-J4 effects.

resultsH19 silencing in both PC-3 and 22Rv1 cells increased: i) E-cadherin and β4 integrin expression as well as proliferation and invasion, ii) in vivo tumor growth, and iii) metastasis formation at bone, lung, and liver. Of note, treatment with GSK-J4 reduced lesions. In parallel, GSK-J4 efficiently induced cell death in PCa-derived OSCs.

conclusionsOur findings underscore the potential of the H19/cell adhesion molecules circuitry as a targeted approach in PCa treatment. Modulating this interaction has proven effective in inhibiting tumor growth and metastasis, presenting a logical foundation for targeted therapy.

Indexed as

lncRNALysine demethylaseMetastasisPreclinical models

Identifiers

PMID38317193
PMCPMC10845766

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.